Welcome to our dedicated page for CYDUCT DIAGNOSTICS news (Ticker: CYDX), a resource for investors and traders seeking the latest updates and insights on CYDUCT DIAGNOSTICS stock.
CYduct Diagnostics Inc. is a leading medical device company focused on revolutionizing women's healthcare, with a primary focus on breast health and wellness. The company is committed to developing innovative testing methods that prioritize clinical integrity, patient privacy, and convenience. With a history of providing quality medical products for over 30 years, CYduct is dedicated to advancing solutions for the early assessment and detection of breast cancer. Their groundbreaking research and development efforts aim to empower women and healthcare providers in the fight against breast cancer.
CYduct Diagnostics (OTC Pink: CYDX), a clinical-stage diagnostic company specializing in early breast cancer detection technologies, has announced its participation in The Reg A & Crowdfunding Conference. The event is scheduled for June 20, 2024, at the Westchester Country Club in Rye, New York. Dom Gatto, the President and CEO, will be available for meetings during the conference. Attendees can connect with him through the conference app. For registration details, please follow the provided link.
CYduct Diagnostics will present at the 2024 Yale Innovation Summit on May 29-30 in New Haven, CT. The company, specializing in non-invasive intraductal breast health technology, will showcase study data on its proteomic technology, which aims to enhance breast cancer detection and patient care. The Summit, celebrating its 10th year, is a major event in the innovation sector, featuring industry leaders from various fields. CYduct's CEO, Dom Gatto, highlighted the benefits of molecular innovations, emphasizing the company's role in improving diagnostic accuracy, reducing unnecessary surgeries, and enhancing early detection and treatment of breast cancer.
CYduct Diagnostics (OTC PINK:CYDX) announced its clinical team won a prestigious grant at the 11th International Symposium on the Human Breast, held by the Dr. Susan Love Foundation. This grant from the Sharon D. Lund Foundation will support the development of a novel proteomic breast cancer risk assessment test utilizing targeted biomarkers. During the symposium, the clinical team presented findings aimed at empowering women with a simple, non-invasive method to assess their breast cancer risk. CEO Dom Gatto highlighted the enthusiastic support from breast cancer advocates, emphasizing the potential impact of their technology on women's health.
FAQ
What is the current stock price of CYDUCT DIAGNOSTICS (CYDX)?
What is the market cap of CYDUCT DIAGNOSTICS (CYDX)?
What is CYduct Diagnostics Inc. focused on?
How long has CYduct Diagnostics Inc. been providing medical products?
What is the primary goal of CYduct Diagnostics Inc.?
How does CYduct Diagnostics Inc. empower women and healthcare providers?
